30/08 – 02/09/2024 | London
ESC 2024
NHỮNG ĐIỂM NỔI BẬT TỪ HỘI NGHỊ TIM MẠCH CHÂU ÂU
SIÊU ÂM TIM GẮNG SỨC ĐỂ CHẨN ĐOÁN VÀ PHÂN TẦNG NGUY CƠ TRONG HFpEF: THANG ĐIỂM BREATH2
ĐƯỢC TRÌNH BÀY BỞI MASARU OBOKATA | 01-09-2024
PC-VN-104313
* OMI (Occlusion Myocardial Infarction), nhồi máu cơ tim do co thắt mạch vành
ACR, albumin-creatinine ratio
AE, adverse event
AESI, adverse event of special interest
AF, atrial fibrillation
AMD, adjusted mean difference
AUC, area under the curve
BNP, B-type natriuretic peptide
CI, confidence interval
CKD, chronic kidney disease
CV, cardiovascular
CVD, cardiovascular disease
DM, diabetes mellitus
ECG, electrocardiogram
eGFR, estimated glomerular filtration rate
ESC, European Society of Cardiology
Hb, hemoglobin
HF, heart failure
HFA, Heart Failure Association
HFpEF, heart failure with preserved ejection fraction
HFrEF, heart failure with reduced ejection fraction
HR, hazard ratio
HTN, hypertension
KDIGO, Kidney Disease: Improving Global Outcomes
LV, left ventricle
MACE, major adverse cardiovascular events
MI, myocardial infarction
MRA, mineralocorticoid receptor antagonist
NSTEMI, non-ST-segment elevation myocardial infarction
NT-proBNP, N-terminal pro B-type natriuretic peptide
OD, once daily
OMI, occlusion myocardial infarction
PAD, peripheral artery disease
RASi, renin-angiotensin system inhibitors
SAE, serious adverse event
SGLT2i, sodium-glucose cotransporter 2 inhibitor
SOC, standard of care
SR, sinus rhythm
STEMI, ST-segment elevation myocardial infarction
UK, United Kingdom
US, United States